A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 25 Jun 2017 Final 8 year results from the study, presented at the 22nd Congress of the European Haematology Association.
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2016 Status changed from active, no longer recruiting to completed.